Twin Focus Capital Partners’s Cartesian Therapeutics RNAC Stock Holding History

Twin Focus Capital Partners’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$120K	Hold	19,500	–	–	0.01%	172
2025 Q4	$141K	Hold	19,500	–	–	0.02%	179
2025 Q3	$199K	Buy	19,500 +500	+3%	+$5.62K	0.03%	183
2025 Q2	$197K	Buy	19,000 +4,000	+27%	+$42.6K	0.03%	164
2025 Q1	$198K	Buy	15,000 +3,000	+25%	+$53.6K	0.03%	152
2024 Q4	$215K	Hold	12,000	–	–	0.03%	137
2024 Q3	$193K	Buy	12,000 +2,000	+20%	+$31.2K	0.03%	144
2024 Q2	$270K	Buy	+10,000	New	+$239K	0.04%	123

Other funds holding RNAC

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Twin Focus Capital Partners's RNAC Position: Q1 2026 in Review

Twin Focus Capital Partners held its Cartesian Therapeutics (RNAC) position steady in Q1 2026 at 19,500 shares worth $120K. The position accounts for 0.01% of the portfolio, ranked #172.

Twin Focus Capital Partners first reported a position in RNAC in Q2 2024 and has held it in 8 quarters since. The position peaked at $270K in Q2 2024. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

Twin Focus Capital Partners held 19,500 shares of Cartesian Therapeutics worth $120K as of Q1 2026.
Twin Focus Capital Partners left its Cartesian Therapeutics share count unchanged in Q1 2026.
Cartesian Therapeutics made up 0.01% of Twin Focus Capital Partners's portfolio in Q1 2026, its #172 holding.
Twin Focus Capital Partners first reported a position in Cartesian Therapeutics in Q2 2024 and has held it in 8 quarters since.
Twin Focus Capital Partners's Cartesian Therapeutics position peaked at $270K in Q2 2024.
83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Twin Focus Capital Partners's 13F filing for Q1 2026, filed 14 May 2026.